Data from Pharmawand - Curated by Marshall Pearce - Date added 12 January 2018

The National Institute for Health and Care Excellence (NICE) has, in its guidelines, recommended Simponi (golimumab) from Merck Inc., as a treatment for ankylosing spondylitis in adults whose disease has responded inadequately to Non-steroidal anti-inflammatory drugs (NSAIDS) or adults who cannot tolerate NSAIDS. NICE has recommended, in the past, Humira (adalimumab), Enbrel ( etanercept) and Cimzia (certolizumab pegol) for the condition and has stipulated that the cheapest of these therapies will be selected to treat the condition .


You will need to login, to leave a comment. is not monitored for collection of adverse event reports. Any adverse events should be reported to your national reporting agency and/or the manufacturer.

Learning Zones

An Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.



See information on psoriasis pathophysiology, signs and symptoms, comorbidities, treatment options, and more.

+ 2 more

IL-17A in Psoriasis

IL-17A in Psoriasis

Experts discuss new targeted therapies for psoriasis at the European Association of Dermatology and Venereology (EADV) Congress.

+ 1 more

Acute and Advanced Heart Failure

Acute and Advanced Heart Failure

What are the most effective treatments for acute heart failure? Can you define advanced heart failure? Discover here...

+ 3 more

Load more

Related Content